Cargando…
Letrozole in the neoadjuvant setting: the P024 trial
Neoadjuvant chemotherapy trials have consistently reported lower response rates in hormone receptor-positive (HR+) breast cancer when compared with HR− cases. Preoperative endocrine therapy has therefore become a logical alternative and has gained considerable momentum from the finding that aromatas...
Autores principales: | Ellis, Matthew J., Ma, Cynthia |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer US
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001223/ https://www.ncbi.nlm.nih.gov/pubmed/17912634 http://dx.doi.org/10.1007/s10549-007-9701-x |
Ejemplares similares
-
Letrozole in the neoadjuvant setting the P024 trial
por: Ellis, Matthew J., et al.
Publicado: (2007) -
Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
por: Ellis, Matthew J., et al.
Publicado: (2008) -
Letrozole in the extended adjuvant setting: MA.17
por: Goss, Paul E.
Publicado: (2007) -
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients
por: Fasching, Peter A, et al.
Publicado: (2014) -
Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)
por: Kim, Jisun, et al.
Publicado: (2014)